CTLA4 and cancer: Moreover, combination therapy involving anti‐PD‐1 or anti‐CTLA4 agents has substantially enhanced treatment response and survival rates in cancer patients.[60, 76, 77] To investigate the potential synergistic effect of combining MAP and anti‐CTLA4 antibody therapy in the context of immunosuppression, we conducted an experiment in which female C57BL/6J mice were subcutaneously implanted with MC38 and Lewis cells.